IDRI and Medicago will present at World Vaccine Congress
IDRI, a Seattle-based non-profit research organization, and Medicago, a Quebec City-based biopharmaceutical company that develops virus-like particles, collaborated on the study to develop the H5N1 vaccine candidate. The trial combined Medicago's VLP vaccine with IDRI's glucopyranosyl lipid A adjuvant.
The trial focused on evaluating the immunogenicity and safety of the vaccine candidate when administered intradermally or intramuscularly. The trial was funded by a multi-million dollar grant awarded to IDRI from the Defense Advanced Research Projects Agency to investigate a novel adjuvant with a Nicotiana benthamiana-produced vaccine candidate.
"This trial is an important step toward development of an influenza vaccine that could be rapidly and widely administered in case of a pandemic outbreak," Steven Reed, the founder of IDRI, said.
Medicago uses a plant-based expression system to develop vaccines, which is faster than the traditional route of using eggs to produce flu vaccines.
In animal studies, IDRI's GLA adjuvant was shown to expand the cross reactivity of antibodies induced by the H5N1 vaccine to other possible pandemic influenza strains, including H2N2.
The World Vaccine Congress will be held at the Gaylord National Hotel and Convention Center in Washington, D.C. between April 16 and April 18.